Latest Insider Transactions at Calithera Biosciences, Inc. (CALA)
This section provides a real-time view of insider transactions for Calithera Biosciences, Inc. (CALA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Calithera Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Calithera Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 27
2023
|
Deepika Pakianathan Director |
SELL
Open market or private sale
|
Indirect |
121,333
-100.0%
|
$0
$0.39 P/Share
|
|
Jan 23
2023
|
Christopher Molineaux SR. VP, DEVELOPMENT |
SELL
Payment of exercise price or tax liability
|
Indirect |
217
-0.77%
|
$0
$0.45 P/Share
|
|
Jan 23
2023
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-4.8%
|
$0
$0.45 P/Share
|
|
Jan 23
2023
|
Susan Molineaux PRESIDENT & CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
526
-1.85%
|
$0
$0.45 P/Share
|
|
Jan 23
2023
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
79
-2.18%
|
$0
$0.45 P/Share
|
|
Jan 23
2023
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
279
-3.19%
|
$0
$0.45 P/Share
|
|
Jan 21
2022
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
666
-0.98%
|
$0
$0.49 P/Share
|
|
Jan 21
2022
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
4,794
-2.71%
|
$0
$0.49 P/Share
|
|
Jan 21
2022
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,586
-4.06%
|
$0
$0.49 P/Share
|
|
Jan 21
2022
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
4,794
-3.29%
|
$0
$0.49 P/Share
|
|
Jan 04
2022
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,077
-11.61%
|
$0
$0.66 P/Share
|
|
Jan 04
2022
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
18,077
-9.26%
|
$0
$0.66 P/Share
|
|
Jan 04
2022
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,855
-5.36%
|
$0
$0.66 P/Share
|
|
Jan 04
2022
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
18,077
-11.03%
|
$0
$0.66 P/Share
|
|
Nov 11
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
48,190
-42.17%
|
$0
$0.88 P/Share
|
|
Nov 10
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
30,000
-20.79%
|
$0
$0.86 P/Share
|
|
Nov 10
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Open market or private purchase
|
Indirect |
100,000
+15.22%
|
$0
$0.85 P/Share
|
|
Nov 10
2021
|
Jonathan G Drachman Director |
BUY
Open market or private purchase
|
Direct |
200,000
+50.0%
|
$0
$0.86 P/Share
|
|
Nov 10
2021
|
Susan Molineaux PRESIDENT & CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+15.22%
|
$0
$0.85 P/Share
|
|
Nov 09
2021
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
51,810
-26.42%
|
$0
$0.84 P/Share
|
|
Nov 08
2021
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
15,566
-8.68%
|
$0
$0.87 P/Share
|
|
Nov 08
2021
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,077
-4.25%
|
$0
$0.87 P/Share
|
|
Nov 08
2021
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,566
-9.09%
|
$0
$0.87 P/Share
|
|
Nov 08
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
15,566
-7.38%
|
$0
$0.87 P/Share
|
|
Nov 05
2021
|
Francesco Parlati SR. VP, RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.32%
|
-
|
|
Nov 05
2021
|
Emil Kuriakose CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+14.21%
|
-
|
|
Nov 05
2021
|
Sumita Ray Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+10.26%
|
-
|
|
Nov 05
2021
|
Stephanie Wong Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+14.9%
|
-
|
|
Nov 05
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+12.45%
|
-
|
|
Nov 05
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+10.48%
|
-
|
|
Nov 05
2021
|
Keith Orford Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+13.27%
|
-
|
|
Oct 28
2021
|
Francesco Parlati SR. VP, RESEARCH |
SELL
Payment of exercise price or tax liability
|
Direct |
45,965
-23.52%
|
$45,965
$1.89 P/Share
|
|
Oct 28
2021
|
Stephanie Wong Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
45,965
-24.54%
|
$45,965
$1.89 P/Share
|
|
Oct 28
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
SELL
Payment of exercise price or tax liability
|
Direct |
45,965
-20.26%
|
$45,965
$1.89 P/Share
|
|
Oct 27
2021
|
Francesco Parlati SR. VP, RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+31.53%
|
-
|
|
Oct 27
2021
|
Sumita Ray Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+27.91%
|
-
|
|
Oct 27
2021
|
Stephanie Wong Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+32.46%
|
-
|
|
Oct 27
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+28.46%
|
-
|
|
Oct 27
2021
|
Keith Orford Director |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+35.14%
|
-
|
|
Oct 27
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+28.41%
|
-
|
|
Jan 20
2021
|
Stephanie Wong Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+27.45%
|
-
|
|
Jan 20
2021
|
Eric Sjogren SR. VP, DRUG DISCOVERY |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+20.29%
|
-
|
|
Jan 20
2021
|
Francesco Parlati SR. VP, RESEARCH |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+25.31%
|
-
|
|
Jan 20
2021
|
Keith Orford Director |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+35.72%
|
-
|
|
Jan 20
2021
|
Sumita Ray Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+28.7%
|
-
|
|
Jan 20
2021
|
Susan Molineaux PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+47.22%
|
-
|
|
Jan 20
2021
|
Christopher Molineaux SR. VP, DEVELOPMENT |
BUY
Grant, award, or other acquisition
|
Direct |
42,000
+30.8%
|
-
|
|
Jan 20
2021
|
Curtis Hecht CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+30.24%
|
-
|
|
Dec 16
2020
|
Keith Orford Director |
SELL
Open market or private sale
|
Direct |
2,447
-18.07%
|
$14,682
$6.0 P/Share
|
|
May 21
2020
|
Bvf Partners L P > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,283,598
-26.01%
|
$13,701,588
$6.0 P/Share
|